<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325193</url>
  </required_header>
  <id_info>
    <org_study_id>MM640G</org_study_id>
    <nct_id>NCT02325193</nct_id>
  </id_info>
  <brief_title>&quot;MiniMed 640G System&quot; User Evaluation With the Question of Reducing the Rate of Hypoglycemia</brief_title>
  <official_title>Prevention of Hypoglycaemia Using the Minimed®640G System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinderkrankenhaus auf der Bult</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic International Trading Sarl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinderkrankenhaus auf der Bult</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Minimed®640G system (MM640G) consists of a combination of insulin and glucose sensor for
      continuous glucose monitoring (CGM). Here, the glucose sensor transmits not only the
      continuous glucose data on the display of insulin pump but, in the case of hypoglycemia also
      interrupt their insulin delivery of pump. In the currently available system Paradigm®VEO, the
      interruption takes place at a settled threshold level. In difference in the new system MM640G
      the shutdown algorithm can already be proactive and help avoid hypoglycemia completely. The
      so called PLGM algorithm (predictive low glucose management) should be tested in the user
      evaluation. The main objective is to answer the question of reducing the rate of hypoglycemia
      by application of the new PLGM algorithm.

      Included are a total of 24 patients, aged 1-21 years, in three pediatric diabetes centers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first phase of two weeks, the sensor-augmented pump therapy (SaP) is carried out
      without these interruption PLGM algorithm. In a second phase for 6 weeks, the PLGM function
      is set. Both phases are compared in terms of the rate of hypoglycemia, the time spent and the
      area under the curve (AUC) glucose range (values &lt;70 mg / dl (3.9 mmol / l)).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>average AUC/day in hypoglycaemic range &lt; 70mg/dl (3,9mmo/l)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of PLGM activities</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimed®640G system</intervention_name>
    <description>Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  patients with type 1 diabetes

          -  CSII since 3 month at least
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes, diagnosed since 12 month at least

          -  continuous subcutaneous insulin infusion (CSII) since 3 month at least

          -  stable outcome since 3 month at least

          -  willingness of patients/ parents to wear a glucose sensor for 2 month

          -  willingness of patients/ parents to use the Minimed®640G system

          -  willingness of patients/ parents to complete a diary

          -  willingness of patients/ parents to comply the requirements of the study protocol

        Exclusion Criteria:

          -  longer absence of the patients (not able to attend the study visits)

          -  subject with allergy of sensor or specific sensor components

          -  communication problems

          -  significant history of eating disorder, anorexia, bulimia

          -  pregnancy

          -  significant history of drug abuse or/ and alcoholism

          -  patient do not want to attend the trial

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Danne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinder - und Jugendkrankenhaus AUF DER BULT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinder - und Jugendkrankenhaus AUF DER BULT</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kinderkrankenhaus auf der Bult</investigator_affiliation>
    <investigator_full_name>Thomas Danne</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

